Skip to main content

Detailed Information

  • November 11, 2018
    1:00pm - 5:00pm
    Type: Short Course
    Capacity: 83


    Reimbursement agencies require real-world evidence on the effectiveness and cost-effectiveness of new drugs and medical devices. In many settings, randomised controlled trial (RCT) data is unavailable or insufficient. Where non-randomised data is used to estimate treatment effectiveness and cost-effectiveness, the main methodological challenge is selection bias from confounding by indication. Standard regression or propensity score methods are frequently used to adjust for selection bias, but estimates of treatment effectiveness may be highly sensitive to the chosen parametric form of these models, and evidence that relies on such methods may be viewed as insufficient by reimbursement agencies. While new, more advanced methods for allowing for confounding cannot offer a panacea, they have...